8-KEarnings & ResultsExhibits & Filings

JOHNSON & JOHNSON 8-K Report, Financial Results (Oct 14, 2008)

Filed October 14, 2008For Securities:JNJ

Summary

Johnson & Johnson (JNJ) filed an 8-K on October 14, 2008, to announce its third-quarter results for the period ended September 28, 2008. The filing primarily consists of a press release detailing the company's sales and earnings performance. Investors should note that this report serves as a notification and provides the official financial figures for the quarter. The detailed financial statements and supplementary sales data are attached as exhibits for further review. While the 8-K itself is procedural, the attached press release contains the core financial information investors need to assess JNJ's performance during the third quarter of 2008, a period likely influenced by broader economic conditions. Key to understanding JNJ's performance will be the details within the press release (Exhibit 99.15) and the unaudited comparative supplementary sales data (Exhibit 99.2). Investors should look for trends in sales growth across JNJ's various segments (Pharmaceuticals, Medical Devices and Diagnostics, and Consumer Health), earnings per share figures, and any management commentary regarding future outlook or challenges. Given the date of the filing, it's important to consider the macroeconomic environment of late 2008 and its potential impact on the company's results and future guidance.

Key Highlights

  • 1Johnson & Johnson (JNJ) filed an 8-K on October 14, 2008, reporting on its third-quarter 2008 financial results.
  • 2The primary purpose of the filing was to disseminate the company's sales and earnings for the quarter ended September 28, 2008.
  • 3The filing includes a press release (Exhibit 99.15) containing the detailed third-quarter financial and operational information.
  • 4Unaudited comparative supplementary sales data and condensed consolidated statements of earnings are also provided as exhibits.
  • 5This report allows investors to review JNJ's performance metrics for the specified quarter.
  • 6The information provided is crucial for assessing the company's financial health and operational success during a challenging economic period.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially announce and provide investors with Johnson & Johnson's sales and earnings results for the third quarter of 2008, which ended on September 28, 2008. It serves as a notification of the company's financial performance for that period.

The detailed financial results, including sales and earnings data, are primarily contained within the press release attached as Exhibit 99.15 to this 8-K filing. Additionally, Exhibit 99.2 provides unaudited comparative supplementary sales data and condensed consolidated statements of earnings for the third quarter.

Investors should look for key performance indicators such as total sales, sales by business segment (Pharmaceuticals, Medical Devices and Diagnostics, Consumer Health), earnings per share (EPS), net income, and any commentary on the company's outlook or factors influencing the results. Examining the comparative sales data will help understand year-over-year trends.

The third quarter of 2008 was a period of significant global economic turmoil, marked by the unfolding financial crisis. Investors should consider how factors like reduced consumer spending, increased credit market tightness, and potential impacts on healthcare budgets might have affected Johnson & Johnson's sales and profitability.